Negative Control

Phase 3Small molecule

GSK

Negative Control is one of 46 small molecule programs targeting Androgenetic Alopecia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Androgenetic AlopeciaActive, not recruiting

GingivitisActive, not recruiting

Androgenetic AlopeciaPhase 1

Active, not recruiting

GingivitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

62 competitors in Androgenetic Alopecia

#DrugCompanyPhaseTrials

Rogaine

Pfizer

Approved

11 2

Depakote

Zyrtec

2 4

Avodart

Akero Therapeutics

Phase 3

4 5

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 2

—6

XEOMIN

MMerz Pharmaceuticals GmbH

Zolymbus

1 8

Platelet Rich Plasma

ZZagazig University

Phase 2

2 9

Lactobacillus Reuteri

TTulane University School of Medicine

Phase 2

1 10

Stem Cells

KKang Stem Biotech Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Irritation2 trials

A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers

Completed·UUNION therapeutics·Phase 1·NCT03301870·36 enrolled

A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects

Completed· GSK logo

GSK·Phase 1·NCT01984775·52 enrolled

Androgenetic Alopecia1 trial

Photosensitization Study in Androgenetic Alopecia

Completed·PPolichem S.A.·Phase 1·NCT02791243·58 enrolled

Gingivitis1 trial

Anti-gingivitis Mouthrinse

Completed·CColgate Palmolive·Phase 3·NCT06048627·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Negative Control. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Negative Control compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Negative Control. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

Negative Control

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Irritation2 trials

Androgenetic Alopecia1 trial

Gingivitis1 trial

References

Drug Info

Quick Facts

Related News